

3. (AMENDED) The method according to claim 2, [characterized in that] wherein the allergen [correspond] corresponds to a non-secreted protein from A. fumigatus.

Sub C2
4. (AMENDED) The method according to claim 1, wherein the [anyone of claims 1-3, characterized in that said] one or more allergens are selected [among] from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.

5. (AMENDED) The method according to claim 1, wherein the [anyone of claims 1-3, characterized in that said] one or more allergens are selected [among] from the group consisting of rAsp f8 and ABPA-related fragments thereof.

Sub G1
6. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-4, characterized in that] an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens[, in particular antibodies of the IgE class or IgG class or subclasses thereof].

7. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-5, characterized in that] antibodies of the IgE class are determined.

Sub G2
8. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-4, characterized in that] an in vivo test is carried out in the individual.

Sub C3
9. (AMENDED) The method according to claim 7, [characterized in that] wherein the test is a skin test involving placing said one or more ABPA-related allergens in the skin of the patient.

7
10. (AMENDED) The method according to claim ²7, [characterized in that] wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens[, in particular antibodies of the IgE class or IgG class or subclasses thereof].

8
11. (AMENDED) The method according to claim 10, [characterized in that] wherein antibodies of the IgE class are determined.

9
12. (AMENDED) The method according to claim 8, [characterized in that] wherein an in vivo test is carried out in the individual.

10
13. (AMENDED) The method according to claim 12, [characterized in that] wherein the test is a skin test involving placing said one or more ABPA-related allergens in the skin of the patient.

Please add the following claims 14-20:

11
--14. (NEW) The method according to claim 6, wherein antibodies of the IgE class or IgG class, or subclasses thereof, are determined.--

12
--15. (NEW) The method according to claim 10, wherein antibodies of the IgE class or IgG class, or subclasses thereof, are determined.--

--16. (NEW) The method according to claim 2, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.--

--17. (NEW) The method according to claim 3, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.--

--18. (NEW) The method according to claim 2, wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof.--

--19. (NEW) The method according to claim 3, wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof.--

17
--20. (NEW) The method according to claim 15, wherein an in vivo test is carried out in the individual.--